Just Diagnosed?

Rapid treatment and SYMTUZA®

Beginning treatment as soon as possible is important for your immediate health and may reduce the risk of passing HIV to others1. Once you and your healthcare provider decide to start treatment, they may recommend SYMTUZA® because it contains an ingredient called darunavir. The Department of Health and Human Services (DHHS) recommends a regimen containing darunavir when a patient begins treatment prior to the availability of resistance testing results, often called rapid initiation. Your healthcare provider may still test your blood and urine to make sure that SYMTUZA® is the right treatment for you.

What is rapid initiation?

 

 

Why treat HIV rapidly?

 

SYMTUZA® is the first one-pill, once-daily medication proven in a clinical trial to effectively treat HIV when prescribed right after diagnosis.

The DIAMOND Study

SYMTUZA® was studied in 109 newly diagnosed HIV patients (within 14 days) who started treatment before receiving lab results. All patients received SYMTUZA®, and the study measured the number of patients who were undetectable (<50 copies/mL) after 48 weeks of treatment.

The DIAMOND study was completed after FDA approval of SYMTUZA®. The safety and effectiveness of SYMTUZA® in patients who had never been treated for HIV was determined in the AMBER study.

A few patients (13 out of 109) left the study for different reasons. Of the remaining 96 patients, 96% reached an undetectable viral load.*

When all 109 patients were accounted for, whether they completed the study or not, 84% reached undetectable and 8% of patients did not reach undetectable (viral load ≥50 copies/mL) after 48 weeks of treatment.

 

*This excludes patients with missing data.

 

The DIAMOND Study showed that 100% of patients on SYMTUZA® were able to decrease their viral load to a low level1 (<200 copies/mL) after 48 weeks.*

 

  • 83% (85/102) at Week 12*
  • 98% (94/98) at Week 24*
  • 100% (96/96) at Week 48*

*This excludes patients who may have discontinued early or had missing data.

SYMTUZA® side effects

Fewer than 1% stopped taking SYMTUZA® because of side effects.

The most common side effects occurring in at least 2% of patients taking SYMTUZA® were diarrhea, nausea, rash, vomiting, and fatigue. These are not the only side effects of SYMTUZA®.

Side effects and discontinuation with SYMTUZA®

Before starting SYMTUZA®, you should get tested for hepatitis B virus and kidney function.

No patients stopped SYMTUZA® due to weight gain, diarrhea, nerve, bone, or kidney function side effects.

 

How satisfied were patients with SYMTUZA®?

In a validated questionnaire, patients in the DIAMOND study had an average score of 58/60, which indicates a high level of satisfaction with SYMTUZA® after 48 weeks of treatment.

Ask your healthcare provider why 97% of people in the same study were satisfied rapidly starting SYMTUZA®.*

*The 96 patients in the study completed the HIV Treatment Satisfaction Questionnaire (HIVTSQs), a 10‐question validated questionnaire that measures patient satisfaction with HIV medications on a scale of 0‐6 (0= low favorability; 6= high favorability) at Week 48. This includes patients who reported a 5 or 6 when asked “how satisfied are you with your present treatment?”; between 87.7% and 99% of patients responded to other individual questions with a score of 5 or 6.

Ready to start treatment?

If you were just diagnosed with HIV, talk to your healthcare provider about rapid initiation and if SYMTUZA® is right for you.

 

Reference:
1. CDC. HIV Treatment as Prevention.
https://www.cdc.gov/hiv/risk/art/index.html.
Accessed January 9, 2020.